May 26, 2024
Plasma Protease C1-inhibitor Treatment Market

The Global Plasma Protease C1-inhibitor Treatment Market is Expected to be Flourished by Rising Prevalence of Hereditary Angioedema

The global plasma protease C1-inhibitor treatment market offers lifesaving treatment options for rare genetic disorders like hereditary angioedema (HAE). Plasma-derived C1-inhibitor replacement therapies help manage symptoms and prevent HAE attacks by replacing low levels of functional C1-inhibitor in patients. These therapies are administered either preventatively to reduce the frequency of HAE attacks or on-demand when early HAE symptoms appear. The global plasma protease C1-inhibitor treatment market offers products like Berinert and Cinryze which are used as short-term prevention or on-demand treatment.

The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The key drivers fueling the growth of the global plasma protease C1-inhibitor treatment market include rising prevalence of hereditary angioedema (HAE) and increasing approvals of novel therapies. According to HAE International, HAE affects about 1 in 50,000 people worldwide. Moreover, only about one-third of HAE patients have been correctly diagnosed. The rising disease prevalence is boosting the demand for effective therapies like C1-inhibitor replacement therapies. Additionally, the approval of new plasma-derived and recombinant C1-inhibitor therapies in recent years has expanded treatment options for HAE patients. For instance, in 2021, the U.S. FDA approved Kalbitor (ecallantide) as the first subcutaneous targeted HAE treatment. These advances in treatment options are driving the growth of this market.

Segment Analysis

The global plasma protease C1-inhibitor treatment market is dominated by the hereditary angioedema (HAE) segment, which accounts for around 80% of market share. HAE is a rare genetic disorder characterized by recurrent episodes of severe edema in the subcutaneous or submucosal tissues. As there is no cure for this condition, treatment focuses on managing the symptoms by inhibiting the C1-esterase enzyme. The high prevalence of HAE segment drives the dominating position of this segment in the plasma protease C1-inhibitor treatment market.

PEST Analysis

Political: The market is regulated by various authorities that approve new drug development and manufacturing practices. Stringent regulations can impact the market growth.

Economic: As the treatments are expensive, public and private health insurance coverage plays a major role in market trends. Global economic growth influences healthcare expenditures.

Social: Increased awareness about rare diseases and availability of effective management options are prompting more patients to seek proper diagnosis and treatment.

Technological: Advancements in protein purification methods and manufacturing technologies aid in developing high quality plasma derived therapies for improved patient outcomes.

Key Takeaways

The Global Plasma Protease C1-inhibitor Treatment Market Growth is expected to witness high over the forecast period of 2024 to 2031, driven by the rising HAE patient pool and innovative treatment options. The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.

Regional analysis:

North America is expected to maintain its dominant position in the market through 2031. This can be attributed to high awareness levels about rare diseases in countries like the US, availability of reimbursement programs as well as presence of leading players. Europe is also a major region due to growing research on plasma therapies.

Key players:

Key players operating in the plasma protease C1-inhibitor treatment market are R&D Systems, Koninklijke Philips N.V., and Panasonic Corporation. Berinert by CSL Behring was the first FDA approved C1-inhibitor treatment and continues to be a major brand. HAEGARDA by CSL Behring is a subcutaneous administration alternative. TAKHZYRO by Shire is a prophylactic medication.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it